FIELD: biotechnology.
SUBSTANCE: disclosed is an isolated binding protein which selectively binds to TGFβ1. Said binding protein is dimer scFv-Fc. Also disclosed is use of said binding protein in a pharmaceutical composition for treating human diseases, such as fibrous disease, cancer, diffuse skin system sclerosis, a disease characterized by disturbed bone tissue remodeling, or kidney disease.
EFFECT: invention provides selective binding and neutralization of TGFβ1 activity with high affinity and avidity; scFv-Fc dimers are candidates for therapeutic routes of use due to combination of their smaller size, high selectivity, activity with respect to TGFβ1 and prolonged half-life in vivo.
12 cl, 7 dwg, 3 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED IGG ANTIBODIES WHICH BIND TO A TRANSFORMING GROWTH FACTOR BETA-1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2728858C2 |
| TRISPECIFIC BINDING MOLECULES FOR TREATING VIRAL HEPATITIS B INFECTION AND BOUND STATES | 2016 |
|
RU2733496C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| 5T4 AND 4-1BB ANTIGEN-BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | 2018 |
|
RU2804458C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| IMPROVED ANTIGEN-BINDING RECEPTORS | 2018 |
|
RU2825816C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| TETRAVALENT ANTIBODIES TO PSGL-1 AND THEIR APPLICATIONS | 2017 |
|
RU2766000C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
